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Abstract
During breast cancer metastasis, cells emigrate from the primary tumor to the bloodstream, which
carries them to distant sites where they infiltrate and sometimes form metastases within target
organs. These cells must penetrate the dense extracellular matrix comprising the basement
membrane of the mammary duct/acinus and migrate toward blood and lymphatic vessels,
processes that mammary tumor cells execute using primarily Epidermal Growth Factor (EGF)-
dependent protrusive and migratory activity. Here, we focus on how the actin regulatory protein
Mena affects EGF-elicited movement, invasion and metastasis. Recent findings indicate that, in
invasive migratory tumor cells, Mena isoforms that endow heightened sensitivity to EGF and
increased protrusive and migratory abilities are up-regulated, while other isoforms are selectively
down-regulated. This change in Mena isoform expression enables tumor cells to invade in
response to otherwise benign EGF stimulus levels and may offer an opportunity to identify
metastatic risk in patients.
Introduction
A traditional view of metastasis holds that metastases results from a process similar to
Darwinian evolution involving the natural selection of tumor cells that are capable of
migration and survival at distant sites. In this model, the selection of tumor cells exhibiting
stable genetic changes occurs; these selected cells are very rare and cause metastasis late in
tumor progression [1]. The recent development of new technologies, including high-density
microarray-based expression profiling, intravital imaging and the collection of invasive
tumor cells from live tumors, have challenged this traditional model of metastasis. These
technologies have also supplied new diagnostic and therapeutic markers of metastatic
disease. Studies of mammary tumors in mice [2, 3, 4, 5], expression profiling of whole
human breast tumors [6, 7] and collection and profiling of the invasive subpopulation of
tumor cells isolated from rat and mouse mammary tumors [8, 9, 10] indicate that metastatic
ability is acquired at much earlier stages of tumor progression than predicted by the
Darwinian model, is encoded throughout the bulk of the primary tumor, and involves
transient changes in gene expression.
These results may be reconciled with the Darwinian model if the selection of stable genetic
changes in the primary tumor during progression contributes the microenvironments
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necessary to induce the transient changes in gene expression that support the invasive and
metastatic phenotype. The stable genetic changes required for induction of the
microenvironments of invasion and cell dissemination could occur early in progression and
throughout the tumor. The Tumor Microenvironment Invasion Model, which is based on this
idea, holds that the tumor microenvironment initiates the expression of genes that induce
cell motility, invasion and metastasis [9, 10, 11]. In this model, it is proposed that oncogenic
mutations in tumor cells in the primary tumor lead to microenvironments that induce cell
motility in tumor cells and stromal cells. Examples of such microenvironments are increased
microvascular density [12] inflammation [13] and hypoxia [14]. These micro-environments
are speculated to elicit transient and epigenetic changes in gene expression in tumor and
stromal cells that resemble programs of gene expression used to drive morphogenetic cell
movements in the developing embryonic organ. When the primary tumor is located in an
adult organ, tumor microenvironments may trigger the embryonic program of gene
expression of this organ leading to epithelial to mesenchymal transition (EMT) and the
morphogenetic-like movements of cells clinically referred to as invasion and metastasis.
The Tumor Microenvironment Invasion Model predicts that microenvironments causing
invasion and metastasis could appear randomly in time and location in the primary tumor
leading to repeated episodes of invasion and systemic tumor cell dissemination (potentially
leading to metastasis) throughout tumor progression [9]. Consistent with this model,
intravital imaging of experimental mammary tumors demonstrates that only a small
proportion of tumor cells are motile but are distributed throughout the tumor and are
observed most frequently localized in certain areas of the tumor, particularly around peri-
vascular macrophages [15, 16, 17]. Furthermore, genes correlating with metastatic outcome
in a variety of solid tumors appear to be expressed early and throughout the bulk of the
tumor [6, 7] and invasive mammary tumor cells can be collected throughout tumors with
chemoattractant-containing needles [5, 10]. The model is also supported by the observation
that micrometastases are often genetically heterogeneous, suggesting that invasive behavior
is not stably specified [18]. Finally, the Tumor Microenvironment Invasion Model is
generally consistent with our current understanding of how the tumor micro-environment
contributes to invasion and metastasis [19].
Expression profiling of invasive tumor cells collected from primary mammary tumors reveal
an invasion signature — a list of genes whose expression is uniquely altered in invasive
tumor cells — involving motility pathways that account for the migratory and chemotactic
activity of these cells in vivo [8-11]. One of the molecules that was highly up-regulated in
the invasive mammary tumor cells collected in vivo is Mena [10], consistent with
observations that high Mena levels are associated with poor clinical outcome in breast
cancer patients [32, 34]. Mena, an actin regulatory protein, influences several of the motility
pathways of the invasion signature, by controlling actin polymerization that is initiated in
common by these pathways [10, 49]. The frequency of a tripartite structure comprised of
peri-vascular tumor cells expressing high Mena levels juxtaposed to peri-vascular
macrophages within breast cancer patient samples correlates well with the likelihood of
metastatic disease, suggesting that Mena will be a useful prognostic biomarker for
metastasis [33].
The goal of this review is to outline recent approaches developed in mammary tumors to
investigate the properties of the tumor microenvironment and how tumor cells in this setting
can acquire an invasive, metastatic phenotype by changes in gene expression, provide a
background on the Mena protein and summarize recent findings indicating that changes in
Mena expression promote metastatic progression and discuss the possible mechanisms that
underlie Mena's effects on tumor cell behavior.
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Identifying and collecting invasive tumor cells
To detect tumor cell behaviors in primary mammary tumors that resemble “morphogenetic”
cell movements, as described above, much effort has been expended to develop intravital
imaging methods that enable detailed characterization of the behavior of carcinoma and
stromal cells within intact primary tumors [15, 20-24]. The resulting methods yield
quantitative information about individual cell behavior in vivo, permitting analysis of
parameters such as: directional migration toward histological landmarks such as blood
vessels; frequency, velocity and persistence of cell motility; interactions between tumor
cells, extracellular matrix and stromal cells that lead to invasion; and intravasation and
extravasation. These imaging methods are valuable in defining cell behaviors necessary for
invasion, intravasation and extravasation, phenotypes of cells harboring specific mutations,
polarized motility and chemotaxis of cells in vivo, and the definition, size and regulation of
microenvironments in vivo.
In mammary carcinomas, intravital imaging in mice and rats revealed the
microenvironments in which tumor cells undergo migration and intravasation, and the
importance of macrophages in these events (reviewed in [13, 15, 25, 26]). In particular,
chemotaxis of tumor cells toward macrophages was found to be essential for invasion in
primary mammary tumors [5, 27], while chemotaxis of tumor cells toward peri-vascular
macrophages was required for intravasation [16]. Furthermore, invasion, intravasation and
metastasis all involve a paracrine loop between macrophages and tumor cells which secrete
EGF and CSF1, respectively [5, 27].
The point at which tumor cells migrate through the endothelium of blood vessels was
identified as the site of blood vessel docking of at least one peri-vascular macrophage [16].
This detailed information about how tumor cells are attracted to blood vessels led to the
development of the “In vivo Invasion Assay.” This assay mimics a blood vessel's micro-
environment, being comprised of a tube filled with matrigel and EGF or CSF1 to attract
invasive tumor cells and their associated macrophages in vivo as a migrating population of
cells. The In vivo Invasion Assay has enabled the capture of live invasive tumor cells
directly from the microenvironment for expression profiling [8, 10].
Expression profiling of invasive mammary tumor cells collected in vivo
defines an Invasion Signature
Expression profiling of invasive tumor cells obtained from mammary tumors using the In
vivo Invasion Assay revealed the genes correlated with survival, adjuvant-resistance and
chemotaxis of invasive cancer cells inside living mammary tumors [8, 10, 28-31]. These
genes, known collectively as the “Invasion Signature”, fall into well-defined pathways and
are coordinately regulated in metastatic tumor cells [9-11] (Figure 1).
The relevance of the Invasion Signature to the chemotactic migratory behavior of metastatic
cancer cells during invasion and intravasation has been examined in a number of studies. A
major insight to emerge from this body of work is that the motility pathways of the Invasion
Signature define the mechanisms for tumor cell migration in vivo [11]. One of the genes
highly up-regulated in the motility pathways of the Invasion Signature of invasive tumor
cells collected from rat and mouse mammary tumors is Mena [8, 10]. Mena is also up-
regulated in human breast cancer [32-34] as well as pancreatic, colon, gastric and cervical
cancers [35-38].
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Mena and the Tumor Microenvironment of Metastasis
The above results suggest that the level of Mena expression in tumors will be a useful
biomarker for the evaluation of enhanced tumor cell motility and invasion, and metastasis in
human tumors. In addition, as summarized above, invasive carcinoma cells in mouse and rat
mammary tumors intravasate when associated with peri-vascular macrophages, thereby
identifying a metastasis microenvironment as an anatomical structure in tumors [16, 17].
Therefore, we define the tripartite arrangement — identified by triple immunohistochemistry
— of an invasive carcinoma cell (marked by Mena over-expression), a macrophage, and an
endothelial cell as “TMEM,” for Tumor Microenvironment of Metastasis. TMEM has been
identified in human breast tumors using this technique [33]. In a retrospective study, TMEM
density in human breast carcinoma samples was found to predict the development of
systemic, hematogenous metastases. In this study, a case-control analysis was performed on
thirty patients who developed metastatic breast cancer and thirty patients without metastatic
disease. Cases were matched to controls based on currently used prognostic criteria. Primary
breast cancer samples were stained using the triple immunohistochemical method to identify
and count TMEM density. Two pathologists, blinded to outcome, evaluated the number of
TMEM per twenty high-power fields. TMEM density was not correlated with tumor size,
lymph node metastasis, lymphovascular invasion, or hormone receptor status. However,
TMEM density was greater in patients who developed systemic metastases compared to the
patients with only localized breast cancer. In addition, for every increase in TMEM of 10,
the risk of systemic metastasis increased by 90%. TMEM is therefore a novel prognostic
marker for hematogenous metastasis of human breast tumors [33]. This work also illustrates
the power of combining multi-photon imaging with mouse models of breast cancer in the
development of new insights into, and markers for predicting, metastasis, and the
microenvironments essential to dissemination of tumor cells in vivo. The insights into
metastasis provided by multi-photon imaging also help to refine or challenge existing
models for the molecular mechanisms underlying metastatic progression and to develop
hypotheses to be tested using cell biological and molecular approaches in vitro.
Mena and the Ena/VASP family in actin dynamics
As noted above, Mena (also referred to as “ENAH” by the HUGO nomenclature committee
database) is up-regulated in human breast cancer and is a part of the cell motility pathways
identified in the mammary tumor Invasion Signature. Mena is the mammalian ortholog of
Drosphila Enabled (Ena), identified originally as a genetic suppressor of phenotypes caused
by mutations in the Drosophila c-Abl tyrosine kinase homolog [39]. Mena, along with the
highly-related VASP and EVL proteins, comprise the vertebrate members of the Ena/VASP
family, molecules that regulate cell movement, shape and adhesion [40, 41], processes
required during invasion and metastasis. Caenorhabditis elegans and Drosophila
melanogaster each contain a single Ena/VASP ortholog [41]; genetic analysis in both
systems revealed roles for Ena/VASP in neural development [53] and epithelial
morphogenesis [57, 58]. The vertebrate Ena/VASP proteins play pivotal roles in controlling
the movement and morpholology [41] of a variety of cell types including fibroblasts [42],
endothelial cells [48], epithelial cells [57, 59, 60] and neurons [44, 55, 48, 52, 55, 60, 61].
Ena/VASP proteins are also required for a variety of chemotactic responses [49, 56, 62],
such as to the axon guidance factors Netrin (a chemoattractant) and SLIT (a repulsive cue)
[63]. Subsequent work showed that Ena/VASP proteins are required in the early stages of
neurite formation to generate filopodia. Unexpectedly, Ena/VASP proteins enable
exocytosis, mediated specifically by the v-Snare VAMP2, which delivers membrane needed
for the massive increase in surface area that accompanies neurite formation [99].
Interestingly, one way in which Mena expression drives metastasis is by increasing the
amount of secreted protease activity by carcinoma cells [49].
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Most cell types express one or more of the Ena/VASP proteins, which in turn localize to the
leading edges of lamellipodia, the tips of filopodia, focal adhesions, cell-cell junctions and,
in some cell types, in a sarcomeric pattern along stress fibers [41] (Figure 2). Ena/VASP
proteins promote formation of long, sparsely branched actin filament networks [41, 42,
45-47] that modulate the morphology and dynamics of membrane protrusions and ultimately
affect cell shape and motility [42-44]. The number of free barbed ends detected by
incubating permeabilized cells with labeled actin correlates directly with Ena/VASP levels
[48, 49]. Since Ena/VASP proteins do not create new barbed ends by nucleating new actin
filaments under physiological conditions, these findings point to a role for Ena/VASP in
maintaining polymerization-competent barbed ends in vivo [45, 50]. The molecular
mechanism underlying the ability of Ena/VASP to regulate the geometry of actin network
assembly has been recently reviewed (Box 1).
Given the effects of Ena/VASP on actin networks, it is not surprising that one major
function of Ena/VASP is to regulate the dynamics of the unbranched, parallel and bundled
actin filaments that comprise filopodia, and that loss of Ena/VASP function greatly impairs
or eliminates filopodia formation in neurons and a variety of other cell types [51-56]. In
some cell types such as fibroblasts, elevated Ena/VASP activity leads to frequent failure in
effective lamellipodial protrusion due to the relatively long sparsely branched actin networks
that buckle in response to the countervailing forces of membrane tension [42]. Other cell
types, including carcinoma cells, are equipped to translate the effects of elevated Ena/VASP
activity into productive protrusions that lead to cell translocation [49].
Mena isoforms in motility and invasion
Mena, like the other Ena/VASP proteins, contains two conserved domains called “EVH1”
and “EVH2” and a central unstructured proline-rich region (Figure 3, and Box 2). The
EVH1 domain mediates protein-protein interactions important for Ena/VASP localization
and regulation (Box 3). The polyproline-rich region and EVH2 interact with the actin
monomer binding protein profilin and directly with G- and F-actin, respectively [45].
Mena has several unique features not found in the other Ena/VASP proteins that endow it
with the ability to potentiate carcinoma metastasis dramatically. Importantly, alternate
splicing of Mena produces distinct protein isoforms, including an invasion-specific isoform,
“MenaINV” (discussed further below), that has no counterpart in VASP or EVL, and which
is found exclusively in invasive tumor cells.
Analysis of the invasion signature of mammary carcinoma cells revealed that Mena
expression was up-regulated in invasive cells compared to average primary tumor cells [8,
10]. Increased Mena levels were also observed in invasive human breast cancers compared
to normal mammary tissue [32]. As noted above, perivascular tumor cells expressing high
Mena levels are a component of TMEM, a structure whose density in clinical samples
correlates with increased risk of metastatic outcome in breast cancer patients [33]. In
addition to breast cancer, Mena up-regulation has been observed in advanced pancreatic,
colon and cervical carcinomas [35-37, 100].
Mena has a number of features that its paralogs VASP and EVL do not share. The first is an
extended repeat region spanning 70 residues with most of the repeats containing the
consensus, [LM]-E-[QR]-[EQ]-[QR] (abbreviated as “LERER” repeat), which is predicted
to form a coiled-coil structure [101]. The repeat is located between the EVH1 domain and
the proline-rich region. In addition to this unique feature, the Mena message undergoes
extensive alternate splicing to give rise to multiple protein isoforms that are expressed in
specific tissues and cell-types [40] (Figure 3). In contrast, EVL has 1 alternately included
exon and VASP has none. There are 14 constitutively included exons in Mena and 5
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alternately included exons that can all encode protein sequence in frame. There has not been
a comprehensive analysis of which of the possible combinations of alternately included
exons are actually produced as mRNA, nor do we know all of the cell types which produce
the various Mena isoforms.
Cloning Mena cDNA from a breast cancer cell line identified the Mena11a isoform [102].
Analysis of RNA from primary mammary tumor cells collected by FACs, compared to that
expressed in invasive mammary tumor cells collected using the in vivo invasion assay,
revealed that the 11a exon is expressed in tumor cells making up the bulk of the primary
tumor, but this exon is essentially undetectable in the Mena message from invasive tumor
cells [103]. Consistent with this finding, the 11a exon is specific to Mena isoforms
expressed in epithelial cell lines and is not found in mesenchymal cells [100, 102]. In fact,
11a becomes excluded in human mammary epithelial cells that are driven to undergo
epithelial to mesenchymal transition (EMT) by expression of the EMT inducing
transcription factor Twist [104]. The presence of 11a in epithelial cells is driven in part by
the activity of the recently identified epithelial-specific splicing factors ESRP1 and ESRP2
[105]. Mena11a is also expressed in normal ovarian tissue where its inclusion is promoted
by the Fox2 splicing factor [106]. Interestingly, analysis of 21 aggressive ovarian tumors
revealed a reduction in Fox2 levels compared to normal tissue and a concomitant loss of 11a
inclusion in Mena [106]. Therefore, Mena11a appears to be included in epithelial cells and
primary carcinomas but excluded from mesenchymal cells as well as invasive/aggressive
tumor cells.
The alternately included 11a exon encodes 21 amino acids that are inserted in the EVH2
domain, between the FAB sequence and the coiled-coil tetramerization domain. The Mena
paralog EVL also has an alternately included 21 amino acid insertion (“EVL-I”) in an
identical relative location as the 11a insertion site, but the sequences share no similarity
[107]. The site of 11a insertion is adjacent to the F- and G- actin binding sites, and the 11a
insertion can be phosphorylated [102], potentially disrupting actin binding. Therefore, it is
possible that the 11a inclusion affects the way in which Mena interacts with barbed ends and
adds an extra site for phospho-regulation of Mena function.
Three alternately included Mena exons were identified by screening a mouse brain cDNA
library [40]. The largest exon, denoted as “+,” falls adjacent to the proline-rich region and is
itself quite rich in proline. Mena+ is a 798 residue protein (the most widely expressed form
of Mena, denoted “Menaclassic,” is 541 amino acids), however, due to their high proline
content both Mena+ and Menaclassic migrate aberrantly on SDS-PAGE gels at approximately
140kDa and 80kDa, respectively. Western blot analysis of adult tissues has shown that the
140kDa isoform is only readily detected in the brain compared to other organs and tissues
[61]. Two other short exons, denoted “++” and “+++” and encoding 4 and 19 residues,
respectively, were identified in brain cDNAs containing the “+” exon. Both ++ and +++ are
inserted at the same site just C-terminal to the EVH1 domain and between the LERER
repeat. No tissue-specific expression has been identified for Mena++ and Mena+++.
Interestingly, the +++ exon is highly conserved in mammals but is not found in other
vertebrates.
The majority of Mena mRNA up-regulated in the invasive subpopulation of tumor cells
isolated from rat, mouse and human mammary tumors using the In vivo Invasion Assay
contains either the ++ or +++ exon, while strong downregulation of Mena 11a occurs in the
same invasive tumor cells. The upregulation of the ++ or +++ exons persists in circulating
tumor cells isolated from blood [103]. These results suggest that Mena+++ and Mena++ are
the isoforms that may function in metastatic progression.
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This prediction has recently been tested [49] (Roussos et al., unpublished) and findings
suggest that expression of Menaclassic, and Mena+++ (referred to as the “invasion isoform” or
MenaINV) in particular, promotes carcinoma cell invasion in three-dimensional collagen gels
and increases carcinoma cell motility in vivo [49]. Menaclassic and MenaINV localize to and
stabilize invadopodia, actin-rich protrusions required for degradation and movement through
extracellular matrix and possibly invasion across basement membranes, thereby increasing
the invasive and metastatic potential of tumor cells.
Finally, MenaINV plays a sensitizing role in the chemotactic and motility responses of tumor
cells to EGF as expression of MenaINV sensitizes mammary tumor cells to EGF signals by at
least 25- to 50-fold, causing tumor cells to respond to otherwise undetectable EGF levels
[49] (Roussos et al., unpublished). MenaINV regulates the lifetime of actin filament barbed
ends produced by EGF-elicited protrusion; within as little as 20 seconds of stimulation, cells
expressing MenaINV have 80% more free barbed ends than control cells or cells expressing
Menaclassic [49]. The stimulatory effect of MenaINV requires cofilin severing but precedes
the accumulation of Arp2/3 in lamellipodia, indicating that MenaINV acts directly on barbed
ends generated by cofilin severing. Therefore, we propose that MenaINV exerts this
stimulatory effect by delaying barbed end capping (Figure 4). This is an important finding
because cofilin-generated barbed ends of actin filaments are needed to initiate invasive
protrusions during chemotaxis and maintain the motility of crawling tumor cells [10, 49,
108]. The mechanisms underlying the effect of the additional 19 amino acids in the
MenaINV isoform, and the ability of this isoform to potentiate EGF-dependent motility
responses, are under investigation. The present findings, however, indicate that we have
identified a master gene that makes breast cancer cells aMENAble to metastasis.
Concluding remarks and future directions
The identification of MenaINV and direct observation of its effects on tumor cell invasion
and metastasis were made possible through the use of multiphoton imaging and the in vivo
invasion assay. The next challenge is to turn these new insights into tools that can be used to
diagnose, and potentially treat, metastatic disease. As a component of TMEM, Mena
expression is already being used to develop prognostic tests. The development of new
probes to the INV and 11a sequences may prove to be even more powerful and
straightforward predictors of metastatic spread. Furthermore, since Mena deficiency in mice
is compatible with viability, inhibitors of Mena function may be useful tools to prevent
metastatic disease. Finally, given the powerful effects of alternate splicing on Mena, it is
likely that regulation by splicing will alter the properties of many molecules relevant to
morphogenetic cell movements, and cancer onset and progression. Regulation by splicing
may be as, or even more, functionally significant than regulation at the level of gene
expression. Through the use of new sequencing technologies, it should be possible to use the
in vivo invasion assay to identify the entire repertoire of invasion isoforms.
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Box 1
Ena/VASP and the regulation of actin dynamics
How Ena/VASP proteins regulate actin dynamics has been debated in the literature, and,
as this topic has been reviewed recently [45, 109], we will present only a brief overview
of the subject. Multiple distinct models for Ena/VASP function have been proposed over
the past five years. One model proposes that Ena/VASP interacts with the barbed ends of
F-actin filaments and enhances the rate of F-actin polymerization, and delays capping by
barbed end capping proteins (“anti-capping”) [94, 50, 42]. An extension of this model
suggests that the Ena/VASP interaction with profilin:actin complexes facilitates direct
monomer transfer to the barbed ends, increases the rate of filament elongation and
enhances the anti-capping activity [94, 85, 50]. Another study proposed that Ena/VASP
has no effect on filament elongation, suggesting instead that Ena/VASP acts solely to
bundle filaments that are nucleated by formins, which nucleate linear actin filaments and
act as processive (remaining attached to the filament) barbed end elongating factors [97].
Yet a third model proposed that Ena/VASP enhances filament elongation but does not
have anti-capping activity in solution or utilize profilin for monomer transfer to filaments
[95]. In addition, this study suggested that Ena/VASP could block capping of filaments,
but only upon dense clustering on beads that also induced a shift to processive filament
elongation [95].
All of the studies listed above used either bulk polymerization assays or visual assays in
which the actin, but not the Ena/VASP, was labeled. Direct insight into Ena/VASP
function by visual, single-molecule assays has been missing from the field. A recent
study employing a visual assay with labeled VASP found that VASP binding to the
barbed ends of filaments is strongly enhanced by the presence of actin monomer,
suggesting that the F-actin binding activity in VASP combined with monomer binding
impaired all F-actin binding except to the barbed end, which could accommodate the
monomer. Labeled VASP was observed at the tips of elongating filaments and enhanced
the rate of filament growth [111]. Therefore, VASP is in fact a processive actin
polymerase. VASP also enhances the rate of filament elongation in the presence of
profilin, supporting the direct monomer transfer model. Importantly, VASP delayed the
rate of filament capping by capping protein six-fold, proving definitively that it has anti-
capping activity [111]. The development of a visual assay for Ena/VASP activity will
allow the field to move beyond this debate over whether VASP has anti-capping activity,
whether it can utilize profilin-actin for polymerization, and whether it is a processive
elongation factor. It will be interesting to see how the other Ena/VASP proteins, and in
particular the various Mena isoforms, behave in similar assays.
A further interesting twist to the study of Ena/VASP function comes from several studies
that suggest various Ena/VASP family members interact genetically with members of the
formin family of actin nucleation/elongation factors. In some cases, Ena/VASP proteins
can be co-immunoprecipitated with formin family proteins including mDia1 [96],
DdDia2 [97] and Drosophila Diaphonous [98]. It is not clear how much of the total pools
of Ena/VASP and the various formins are in complex together, but it is likely to represent
a relatively small fraction of each. While it seems unlikely that Ena/VASP act simply to
bundle filaments behind formins, it will be interesting to determine the functional role of
these Ena/VASP:formin complexes.
Gertler and Condeelis Page 13
Trends Cell Biol. Author manuscript; available in PMC 2012 July 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Box 2
Organization of Ena/VASP proteins
The N-terminal EVH1 domain (for Ena/VASP homology) binds to proteins containing a
specific proline-rich motif that helps localize Ena/VASP proteins and recruit them into
complexes with signaling proteins.
The middle portion of Ena/VASP proteins consists of a proline-rich region that binds a
number of SH3- and WW-domain containing proteins including IRSp53, an I-Bar protein
and Cdc42 effector that promotes filopodial formation [81, 82]. The proline-rich region
also binds to the actin monomer binding profilin proteins, which play diverse roles in
regulating actin dynamics (see recent reviews [83, 84]), including the ability to transfer
bound monomer onto free F-actin barbed ends. Profilin can bind actin monomer and
interact simultaneously with Ena/VASP through a high-affinity profilin-binding site
(termed “loading site” [85]) with the consenus PPP[AP]PPLP [68, 83, 85, 86].
Importantly, profilin:actin complexes have a higher affinity for the loading site than does
profilin alone, suggesting that once actin monomer is transferred from profilin to a
barbed end, exchange of the profilin bound to the loading site for a new profilin:actin
complex would be favored [86]. Interestingly, while VASP and Evl each have a single
loading site, Mena contains four, suggesting it may be capable of more profilin:actin
complexes than its paralogs. Importantly, the poly-Pro loading sites in Ena/VASP
proteins are located adjacent to actin binding motifs contained in the EVH2 domain.
The C-terminal EVH2 domain of Ena/VASP contains binding sites for G- and F-actin
[87, 88], called “GAB” and “FAB”, respectively. The proximity of a poly-Pro loading
site permits Ena/VASP to bind profilin+G-actin complexes through two interfaces
simultaneously: profilin-PPP[AP]PPLP and the adjacent G-actin+GAB. The G-actin in
this complex is oriented towards the FAB motif of Ena/VASP, presumably positioned to
be added on to growing filaments [85]. The organization of binding sites for profilin,
actin monomer and F-actin lead to a model in which profilin:actin binding to the loading
site+GAB is followed by direct transfer of the monomer onto the adjacent F-actin barbed
end and subsequent exchange of profilin for profilin:actin [83][89].
EVH2-mediated interactions with growing ends of actin filaments are required for stable
targeting of Ena/VASP to the leading edge of lamellipodia [42, 51, 91]. The GAB motif
stabilizes Ena/VASP at the tips of filopodia suggesting that it plays a role in recognizing
barbed ends analogous to the barbed end capture activity in the highly-related WH2
domain within N-WASP [51]. Both G- and F-actin interactions are disrupted by
phosphorylation at sites within the EVH2 domain [50, 90], including a protein kinase G
site found in both Mena and VASP [40, 91].
At the very C-terminus of EVH2, a right-handed coiled-coil mediates both homo-
tetramerization and the formation of mixed tetramers containing different family
members [92, 93]. The combination of tetramerization and F-actin binding allows Ena/
VASP to bundle actin filaments [87]; this bundling activity acts to cluster the tips of
elongating filaments during filopodial formation and extension [51], however, a
physiological role for Ena/VASP bundling along the length of filaments in cells has not
been demonstrated.
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Box 3
EVH1-mediated interactions
EVH1 domains bind proteins that contain the consensus: [FL]PXφP, where φ is any
hydrophobic residue [65, 66]. There are a growing number of proteins with EVH1-
binding sites and a full discussion of all such molecules is beyond the scope of this
review, therefore only a few examples will be presented. The first characterized EVH1-
ligand was ActA, a protein found on the surface of the intracellular bacterial pathogen
Listeria monocytogenes that contains four EVH1-binding motifs that recruit host cell
Ena/VASP proteins to the bacterial surface [66]. Listeria employ host cell proteins to
trigger actin polymerization on the bacterial surface to produce a propulsive force that
drives their movement [67] and Ena/VASP recruitment by ActA greatly enhances actin
polymerization and bacterial movement [68, 69]. Zyxin, which helps recruit Ena/VASP
to focal adhesions and stress fibers, contains four EVH1-binding sites [110].
Lamellipodin (Lpd), an adaptor protein containing RA and PH domains that bind Ras and
PI(3,4)P2, respectively, harbors six EVH1-binding sites and plays an important role in
recruiting Ena/VASP to lamellipodia [70, 71]. Silencing Lpd in B16 cells produces a
dramatic reduction in F-actin content, thereby eliminating normal lamellipodial
protrusion. Lpd is a target for Abl/Arg tyrosine kinases and is required along with Ena/
VASP for PDGF-induced dorsal ruffling in fibroblasts [72] and the Drosophila Lpd is
required for normal epithelial morphogenesis [73]. Mig-10, the C.elegans Lpd ortholog,
is required for cell polarization in response to Netrin and for axon guidance responses to
Netrin and Slit [74-76]. The Slit receptor, Robo, binds to Ena/VASP through EVH1-
binding sites in its cytoplasmic tail [63]. Palladin, an actin binding protein and EVH1
ligand [77] has been implicated in metastatic progression; it is upregulated 3.2-fold in the
invasion signature [11], contributes to breast cancer cell invasion [78] and is a target for
the anti-metastatic kinase Akt-1, which blocks Palladin-driven invasion [79]. Finally, the
putative tumor suppressor TES is an unconventional Mena-specific EVH1 ligand that
binds via a LIM domain to a region that overlaps with the [FL]PXφP binding pocket [80].
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Figure 1. The motility and chemotaxis pathways of the Invasion Signature
Expression profiling of invasive tumor cells obtained using the In vivo Invasion Assay
revealed the identities of the genes correlated with the survival, adjuvant-resistance and
chemotaxis of invasive cancer cells inside living tumors. These genes fall into well-defined
pathways and are coordinately regulated in metastatic tumor cells. These pathways are
collectively called the Invasion Signature [8-11]. The motility and chemotaxis pathways of
the Invasion Signature are shown here. Genes highlighted in color are those whose
expression is altered in invasive tumor cells. The extent of over- and under-expression is
indicated next to each as fold change at the mRNA level. Mena is upregulated in rat, mouse
and human invasive mammary carcinoma cells [103]. Mena regulates cell motility by
increasing the elongation of actin filament barbed ends produced by the cofilin and N-
WASP pathways by antagonizing the ability of capping protein to bind barbed ends,
increasing filament elongation rates or both [45]. Mena function may be modulated by
interactions with its binding partners, including Lpd [70], TES [80] and Palladin [77].
Gertler and Condeelis Page 16
Trends Cell Biol. Author manuscript; available in PMC 2012 July 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Distribution of Mena in a primary hippocampal growth cone (top) and an MTLn3
carcinoma cell stimulated with EGF (bottom)
Mena signal is in green, F-actin in red and nuclei are labeled in blue. Mena is concentrated
in filopodial tips, lamellipodia and focal adhesions. Scale bar is 5μm.
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Figure 3. Mena Domain Structure
A schematic of the Mena domain organization and motif locations as described in the text is
depicted. The insertion sites of the alternately-included sequences INV and 11a are
indicated.
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Figure 4. Proposed model for Mena anti-capping/elongation activity in carcinoma cell invasion
Growth factor stimulation leads to activation of cofilin near the plasma membrane.
Activated cofilin severs capped filaments to generate free barbed ends. MenaINV binds the
free barbed ends and promotes filament elongation through a combination of direct actin
monomer transfer from bound profilin:actin to the filament ends and protection from
capping by capping proteins.
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